Advances in organ preserving strategies in rectal cancer patients
- PMID: 29275912
- DOI: 10.1016/j.ejso.2017.11.024
Advances in organ preserving strategies in rectal cancer patients
Abstract
Treatment of rectal cancer patients has been subjected to change over the past thirty years. Total mesorectal excision is considered the cornerstone of rectal cancer treatment, but is also associated with significant morbidity resulting in an impaired quality of life. The addition of neoadjuvant chemoradiotherapy to surgery has shown to improve survival and local control and may lead to a partial or even complete response (CR). This raises questions regarding the necessity for subsequent radical surgery. After careful patient selection local excision and wait-and-see approaches are explored, aiming to improve quality of life without compromising oncological outcome. A multimodality diagnostic approach for optimal staging is crucial in determining the appropriate neoadjuvant treatment regimen. Adequate endoscopic restaging of rectal tumours after multimodality treatment will aid in selecting patients who are eligible for an organ preserving approach. The role and accuracy of imaging in the detection of the primary tumour, residual rectal cancer or local recurrence seems vital. Alternative neoadjuvant regimens are currently explored to increase the rate of clinical CRs, which may support organ preserving approaches. This review aims to generate insight into the advances in diagnostics and treatment modalities in all stages of rectal cancer and will highlight future studies that may support further implementation of organ preservation treatment in rectal cancer.
Keywords: Chemoradiotherapy; Complete response; Downstaging; Imaging; Organ preservation; Rectal cancer.
Copyright © 2017 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
Similar articles
-
Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.Lancet Oncol. 2015 Nov;16(15):1537-1546. doi: 10.1016/S1470-2045(15)00215-6. Epub 2015 Oct 22. Lancet Oncol. 2015. PMID: 26474521 Free PMC article. Clinical Trial.
-
Organ preservation with local excision or active surveillance following chemoradiotherapy for rectal cancer.Br J Cancer. 2017 Jan 17;116(2):169-174. doi: 10.1038/bjc.2016.417. Epub 2016 Dec 20. Br J Cancer. 2017. PMID: 27997526 Free PMC article. Clinical Trial.
-
Management of Rectal Cancer Without Radical Resection.Annu Rev Med. 2017 Jan 14;68:169-182. doi: 10.1146/annurev-med-062915-021419. Epub 2016 Sep 9. Annu Rev Med. 2017. PMID: 27618750 Review.
-
Is it time to rethink the rule of total mesorectal excision? A prospective radiological and pathological study in 49 consecutive patients with mid-rectal cancer.Colorectal Dis. 2016 Sep;18(9):O314-21. doi: 10.1111/codi.13449. Colorectal Dis. 2016. PMID: 27381492
-
Local excision following chemoradiotherapy in T2-T3 rectal cancer: current status and critical appraisal.Updates Surg. 2020 Mar;72(1):29-37. doi: 10.1007/s13304-019-00689-2. Epub 2019 Oct 16. Updates Surg. 2020. PMID: 31621033 Review.
Cited by
-
Can Ex Vivo Magnetic Resonance Imaging of Rectal Cancer Specimens Improve the Mesorectal Lymph Node Yield for Pathological Examination?Invest Radiol. 2019 Oct;54(10):645-652. doi: 10.1097/RLI.0000000000000581. Invest Radiol. 2019. PMID: 31219996 Free PMC article.
-
Changes in surgical therapies for rectal cancer over the past 100 years: A review.Ann Gastroenterol Surg. 2020 May 10;4(4):331-342. doi: 10.1002/ags3.12342. eCollection 2020 Jul. Ann Gastroenterol Surg. 2020. PMID: 32724876 Free PMC article. Review.
-
Before and after Anorectal Surgery: Which Information Is Needed from the Functional Laboratory?Visc Med. 2018 Apr;34(2):128-133. doi: 10.1159/000486693. Epub 2018 Apr 20. Visc Med. 2018. PMID: 29888242 Free PMC article. Review.
-
Oncologic Risk of Rectal Preservation Against Medical Advice After Chemoradiotherapy for Rectal Cancer: A Multicenter Comparative Cross-Sectional Study with Rectal Preservation as Supported by Surgeon.World J Surg. 2019 Dec;43(12):3216-3223. doi: 10.1007/s00268-019-05128-2. World J Surg. 2019. PMID: 31410512
-
Radiotherapy quality assurance for mesorectum treatment planning within the multi-center phase II STAR-TReC trial: Dutch results.Radiat Oncol. 2020 Feb 18;15(1):41. doi: 10.1186/s13014-020-01487-6. Radiat Oncol. 2020. PMID: 32070386 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous